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Abstract
Altered metabolism in cancer cells has been viewed as a passive response required for a malignant transformation.
However, this view has changed through the recently described metabolic oncogenic factors: mutated isocitrate
dehydrogenases (IDH), succinate dehydrogenase (SDH), and fumarate hydratase (FH) that produce oncometabolites that
competitively inhibit epigenetic regulation. In this study, we demonstrate in silico predictions of oncometabolites that have
the potential to dysregulate epigenetic controls in nine types of cancer by incorporating massive scale genetic mutation
information (collected from more than 1,700 cancer genomes), expression profiling data, and deploying Recon 2 to
reconstruct context-specific genome-scale metabolic models. Our analysis predicted 15 compounds and 24 substructures of
potential oncometabolites that could result from the loss-of-function and gain-of-function mutations of metabolic enzymes,
respectively. These results suggest a substantial potential for discovering unidentified oncometabolites in various forms of
cancers.
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Introduction
Otto Warburg observed that cancer cells convert most of their
consumed glucose into lactate, despite the presence of sufficient
oxygen [1]. This metabolic state, called ‘‘aerobic glycolysis’’ of
cancer cells, has been viewed as a passive response required for a
malignant transformation [2], and was originally hypothesized to
be a necessary adaptation offsetting dysfunctional mitochondria.
In contrast to this initial hypothesis, later studies have found that
most tumor mitochondria are not defective in their ability to carry
out oxidative phosphorylation [3–5].
The notion of passive cancer metabolism is being challenged by
recent studies. It was shown that altered metabolism can by itself
be a driver for oncogenic [6–10]. Recently characterized isocitrate
dehydrogenase (IDH1, IDH2) mutations have established a new
paradigm in oncogenesis in that the heterozygous point mutations
confer a new metabolic enzymatic activity that produce an
oncometabolite (e.g. 2-hydroxyglutarate (2-HG), from a-ketoglu-
tarate) (Figure 1A; left). Surprisingly, 2-HG shows a 100-fold
increased concentration in glioma and acute myeloid leukemia’s
(AML) patients with IDH1 or IDH2 missense mutations. This
increased concentration of 2-HG competitively inhibits a-ketoglu-
tarate (a-KG) binding to histone demethylases, thus blocking
differentiation of cells [6,7]. In parallel to IDH, loss-of-function
mutations on succinate dehydrogenase (SDHA, SDHB, SDHC,
and SDHD) and fumarate hydratase (FH) cause the accumulation
of succinate and fumarate, respectively, which also acts a
competitive inhibitor of a-KG-dependent oxygenases that regulate
hypoxia-inducible factor (HIF) oncogenic pathway (Figure 1A;
middle, right) [9–12]. Curiously, although IDH1 and IDH2
mutations are clearly powerful drivers of low grade glioma and
AML, they seem to be rare or absent in other tumor types. This
observation highlights the importance of the specific cellular
context in understanding metabolic perturbations in cancer cells
[6,13].
Metabolism represents a complex network of biochemical
reactions and it may be hard to decipher phenotypic consequences
based on single reaction alterations. Annotated genomes and
biochemical legacy data, however, have enabled the construction
of genome-scale models (GEMs) of metabolism [14,15] that have
been successfully used to compute many observed metabolic states
and properties [16–19]. A GEM is a formal and mathematical
representation of reconstructed metabolism as a genome-scale
network [18,19], which consist of collections of metabolic
reactions, their stoichiometry, the enzymes and the genes that
encode them. GEMs offer a novel mechanistic link between
genetic parameters and computed metabolic states. Two versions
of the human metabolic reconstruction are available [14,20].
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With the rapid development of high-throughput experimental
methods, recent integrative studies using disparate omics data
types have deciphered characteristics of cancer metabolism using
in silico GEMs [21–23]. Shlomi et al. dissected underlying
principles of elevated glycolysis through the simulation of biomass
production rates using GEMs [21]. Folger et al. identified drug
targets for cancers based on synthetic lethal gene pair analysis
using a generic GEM of cancer [22]. Further, the GEM analysis
was applied to hereditary leiomyomatosis and renal cell cancer
(HLRCC) to unravel the survival mechanism that enables the
HLRCC cells to operate the mitochondrial electron transport
chain despite mutations on FH [23]. The GEM of human
metabolism has thus already shown its utility for the analysis and
understanding of cancer metabolism.
In this study, we predict putative oncometabolites by incorpo-
rating genetic mutation information on a massive scale collected
from more than 1,700 cancer genomes into context-specific GEMs
of metabolism for nine cancer types. We reconstructed context-
specific cancer and matching metabolic models from correspond-
ing normal tissue for nine cancer types using gene expression
profiles of primary cancer cells and site-matched normal cells. By
integrating the exome mutation data source with the reconstructed
GEM, we predict potential oncometabolites that could show
altered concentration in cancer cells due to the loss- or gain-of-
function mutations on enzymes (Figure 1B).
Results
Mutation information and gene expression data sets
We collected sets of exome mutation and gene expression data
from The Cancer Genome Atlas (TCGA, http://cancergenome.
nih.gov/), Cancer Cell Line Encyclopedia (CCLE) [24], and
NCBI Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/
geo/) (Table 1). We selected three cancer types (breast, kidney,
and squamous cell carcinoma lung cancer) from the TCGA
project with accompanying publically available genetic mutation
and gene expression data sets. In addition, we collected mutation
information for six types of cancers studied in the CCLE project
(gastric, leukemia, liver, adenocarcinoma lung, ovarian, and
pancreas). As the CCLE project does not provide gene expression
for matched normal samples, we separately collected expression
data of cancer and site-matching normal tissues from the NCBI
GEO database by matching cancer histological types to the CCLE
mutational data. Finally, nine unique histology types of cancer
with mutation and gene expression data measured in cancer and
site-matching normal were used in the present study (Table 1).
Large number of metabolic genes are mutated across
different cancer types
To identify potential oncometabolites that originated from
genomic variations in metabolic enzymes, we determined the total
number of mutations in enzymatic genes across nine cancer types.
The metabolic genes were identified from the global human
metabolic network Recon 2 [14]. For every gene in Recon 2, the
number of coding region genetic variants including classes of
missense, nonsense, frame shift, in frame indel, silent, and splice
site mutations were counted. Between 5 to 20 metabolic genes per
sample were mutated in cancer cells (Figure 2A). Also, when we
tallied the total mutation count per cancer type, the mutational
frequency became more pronounced in each type of cancer
(Figure 2B). In the CCLE data sets (gastric, leukemia, liver,
ovarian, and pancreas), the initial mutation calling was made
within a set of targeted metabolic genes. Thus we expect that the
real number of mutated metabolic genes would be higher than the
current numbers. Second, we confirmed that the missense
mutation, which is the consensus type of mutation observed in
IDH, was the most dominant mutation class in metabolic genes
(Figure 2C). This analysis was also conducted on additional
TCGA mutation data sets, which showed qualitatively similar
results (Table S1 in Text S1, Figure S1 in Text S1).
20 enzymatic genes were selected for oncometabolite
prediction
In order to predict oncometabolites that could originate from
mutations, we selected metabolic genes that are recurrently found
to be mutated in more than 5% of samples. Transporters were
removed from our analysis, as they usually do not represent
canonical metabolic transformations. As shown in the examples of
IDH and FH, mutations could change the enzyme activity such
that it gains a new function (gain-of-function) or loses its original
function (loss-of-function). In this study, we divided the potential
oncometabolites into two categories: (i) native oncometabolites
that could change concentration due to the loss-of-function (LoF)
mutations, and (ii) promiscuous oncometabolites that could change
concentration due to the gain-of-function (GoF) mutations.
Therefore, for this oncometabolites analysis, we classified muta-
tions into two classes. First, we adopted a definition for LoF
mutations to be correlated with loss of function: nonsense (stop
codon introducing), splice site indels&SNP (splice site disrupting
mutations), and frame shift indels (disrupting reading frame) [25]
[26]. Second, we focused on the possibility of missense mutations
as GoF mutations, which is the consensus type of mutation that is
observed in IDH oncometabolite studies. Finally, the recurrently
mutated genes are categorized into three classes: (i) recurrently
mutated genes from a type of GoF mutation, (ii) recurrently
mutated genes from types of LoF mutations (nonsense, frame shift
indels, splite site indels&SNP) [26], and (iii) recurrently mutated
genes from both of GoF and LoF mutations. As a result, we found
96 enzyme encoding metabolic genes that were recurrently
mutated in the nine types of cancer (Figure 3A, File S1).
From the 96 recurrently mutated metabolic genes, we next
selected genes that could have significant functional impacts on
their catalytic activities due to the mutations. First, isoenzymes
were filtered out because an unexpected mutational malfunction of
one isoenzyme could be substituted by functions of other
Author Summary
Cancer and metabolism have been considered to be
associated for a long period since Otto Warburg observed
that tumor cells consume glucose and convert most of it
to lactate, despite the presence of oxygen. However, the
role of the Warburg effect in oncogenesis had been under
doubt because no solid links between genetic variations in
metabolic genes and cancer had been observed until
recent days. When with the development of sequencing
technologies, researchers found mutations in IDH1, IDH2
(isocitrate dehydrogenase) in medium-grade glioma and
acute leukemia. As these mutated metabolic genes initiate
unexpected enzymatic reactions, cancer cells show altered
concentration of particular metabolites, here called ‘‘on-
cometabolites’’. The oncometabolites regulate the epige-
netic controls of cell differentiations. In this study, we
predict potential oncometabolites that might originate
from loss or gain-of-function mutations in nine types of
cancer from massive scale cancer mutation data with a
systems biology approach.
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isoenzymes having duplicated catalytic activities. Second, mutated
genes having smaller functional impact were removed. The impact
of a mutation in the recurrently mutated genes was assessed by
using the functional impact score (FIS) [27] which demonstrated a
consistent higher accuracy in a recent systematic assessment [28].
A FIS is derived from multiple sequence alignments of amino acid
Figure 1. The origin of oncometabolites and an overview of the analysis workflow used. (A) (left) Mutant isocitrate dehydrogenases (IDH)
enzymes show a neomorphic enzymatic activity to convert a-KG (a-ketoglutarate) into 2-HG (2-hydroxyglutarate), a small oncometabolite. The
presence of mutant IDH1 or IDH2 proteins results in increased amounts of 2-HG, which then alters a number of downstream cellular activities. 2-HG
competitively inhibits a-KG binding to several histone demethylases. (Middle, Right) Loss of succinate dehydrogenase (SDH) and fumarate hydratase
(FH) enzymatic activity due to the mutation results in accumulated concentration of intracellular succinate and fumarate, respectively. (B) Overview of
the work presented here. First, recurrently mutated enzymes which could produce potential oncometabolites are identified across the nine cancer
types. Once the recurrently mutated enzymes were identified, oncometabolites were predicted by simulating flux changes between LoF cancer vs.
normal in silico GEM (LoF analysis), and applying the chemoinformatics approach to predict promiscuous catalytic activities of enzymes resulting from
their GoF mutations (GoF analysis).
doi:10.1371/journal.pcbi.1003837.g001
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sequence homologs, thus, the score is based on the evolutionary
conservation of a mutated residue in a protein family. By applying
the aforementioned two criteria, 20 metabolic genes were selected
for detailed analysis. These 20 genes are recurrently mutated in
samples ($ 5%), and are expected to have significant functional
impact from their genomic sequence mutations (Figure 3B,
Figure S2 in Text S1, File S1). Notably, we observed mutation
recurrence in LoF SDHB that is one of the previously identified
oncometabolite-producing enzymatic genes (Table S2, S3 in
Text S1).
Reconstructed cancer and normal metabolic GEMs
correctly characterize in vivo cellular metabolic activity
In order to predict oncometabolites originating from LoF
mutations on enzymes, we simulated flux changes of reactions in
a cancer cell using GEMs. For the reconstruction of cancer
specific and matched normal metabolic networks, gene expres-
sion data sets of cancer and matched normal were used. Here, the
specific characteristics of cancer and normal metabolic models
were represented by the rerouted network structure based upon
the presence or absence of an enzymatic reaction in the
intracellular environment of cancer and normal cells. This
presence or absence of reactions was determined by the
present/absent (P/A) calls of enzymatic genes (see Materials
and Methods for details).
With the result of P/A calls of enzyme-encoding genes in nine
cancer and normal gene expression data sets, we evaluated the
relevance of P/A call results to the cancer specific metabolism.
Here, we first assessed gene-wise P/A alterations in cancer vs.
normal across nine cancer types. In this analysis, we confirmed
that the P/A alterations in cancer vs. normal of enzymatic genes
were not consistent across different cancer types (Figure S3A in
Text S1). This inconsistency is in accordance with previous
finding that the expression differences of individual genes vary
from cancer to cancer [29]. However, when the alterations were
evaluated at the level of functional pathways, several pathways
related to common malignancy features showed significant P/A
alterations (Figure S3B in Text S1). A pathway is considered to
be significantly altered if the pathway is found to have a
significantly higher number of genes with P/A alterations than
the corresponding number found in a random set of genes (see
Text S1 for details). Specifically, reactions transporting (export-
ing, secreting) substances inside and outside of the cell were
frequently altered across nine types of cancer. Furthermore, we
confirmed that these altered pathways had significant over
representation of mutations (Figures S3C-S3E in Text S1).
We reconstructed nine cancer and normal matching models using
P/A gene expression calls the Gene Inactivity Moderated by
Metabolism and Expression (GIMME) algorithm (see Materials
and Methods for details, Table 2, Figures S4-S6 and Tables
S4-S6 in Text S1).
The accuracy of the cancer and normal matched metabolic
models were evaluated based on: (i) how well the structure of the
reconstructed network represents gene expression data, and (ii)
how well the simulated fluxes predict metabolic states of cancer
and normal cells.
Since the characteristics of the reconstructed model are mainly
determined by the result of gene expression P/A calls, we first
evaluated how well the network structure of the model represents
the gene expression P/A calls. Since a gene can be associated with
multiple reactions, or vice versa, the correlation between P/A calls
and the network structure was calculated in two steps. The final
correlation was determined by correlations of two vectors of
Pearson’s correlation coefficient (PCC) calculated from pairwise
correlations of presence/absence of gene expression and pairwise
correlations of presence/absence of reactions between cancer
types (Figure 4A). Correlation coefficients varied from 0.90 to
0.98, and the PCC values were significantly higher than random
Table 1. Types of cancer and mutation and gene expression data sets used.
Cancer type Mutation source Expression source/ platform
(Histological sub type) (No. samples) (No. cancer/ No. normal), [reference]
Breast TCGA TCGA/ Illumina Hiseq RNAseqV2
(Invasive carcinoma) (919) (99/ 99)
Kidney TCGA TCGA/ Illumina Hiseq RNAseqV2
(Renal clear cell carcinoma) (502) (65/ 65)
Lung TCGA TCGA/ Illumina Hiseq RNAseqV2
(Squamous cell carcinoma) (178) (16/ 16)
Gastric CCLE GEO/ Affy HG U133 Plus 2.0 Array
(Adenocarcinoma) (22) (38/ 31), [GSE13911]
Leukemia CCLE GEO/ Affy HG U133A Array
(Acute myeloid leukemia) (34) (26/ 38), [GSE9476]
Liver CCLE GEO/ Affy HG U133A 2.0 Array
(Hepatocellular carcinoma) (25) (22/ 22), [GSE14520]
Lung CCLE GEO/ Affy HG U133A Array)
(Adenocarcinoma) (45) (28/ 28), [GSE7670]
Ovarian CCLE GEO/ Affy HG U133 Plus 2.0 Array
(Carcinoma) (46) (12/ 12), [GSE14407]
Pancreas CCLE GEO/ Affy HG U133 Plus 2.0 Array
(Carcinoma) (44) (36/ 16), [GSE16515]
doi:10.1371/journal.pcbi.1003837.t001
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PCC values (Figure S7 in Text S1). Thus, the reaction content of
the cancer and normal models represent the gene expression data
sets well.
Second, we tested the accuracy of the simulated flux states of
the reconstructed models by evaluating whether the flux states
correctly predict metabolic states of cancer and normal cells. We
hypothesized that if the flux through a reaction was predicted to
increase (or decrease) its magnitude in cancer compared to
normal, then the expression level and/or abundance of the
associated active enzyme in cancer will increase (or decrease) in
order to meet the change in flux. With this hypothesis, we
compared the changing pattern (increase or decrease) between
flux and gene expression for the reactions with a significant flux
change. Flux changes were calculated using the Markov chain
Monte Carlo (MCMC) (see Materials and Methods for
details). Figure 4B shows the accuracy of the predictions for the
significantly changed fluxes (P-value , 0.001, fold-change $ 2).
The results are fairly accurate. Among the nine cancer models,
seven cancer types, except the lung (SCC) cancer and leukemia,
showed significantly better accuracy than random tests (P-value
, 0.05). Furthermore, our results were qualitatively robust with
variations in the P-value and fold-change thresholds (Figure S8
in Text S1)
In addition, we evaluated the accuracy of predicting essential
genes. The accuracy of reconstructed models was evaluated by the
enrichment of in vivo essential genes among in silico essential
genes computed from Flux Balance Analysis (FBA) (see Materi-
als and Methods for details). Across the nine cancer types, we
found that about 3–30% of genes contributed to cell growth, about
2–14% of genes were essential for the cell growth (Figure 4C).
Further, in several cancer types (breast, kidney, lung (SCC), and
liver), we found that genes predicted to have higher contributions
to the biomass formation are more enriched in the in vivo essential
genes (Figure 4D).
The analyses presented here confirm that the simulated flux
through the reconstructed models effectively predicts in vivo
cellular metabolic activity of cancer and normal cells.
15 candidate oncometabolites are predicted as a result
of loss-of-function (LoF) mutations
From the substrates and products of the nine LoF mutant
enzymes (Figure 3B), we chose the metabolites that significantly
change the flux state in cancer cells with LoF mutation activity
relative to the corresponding normal tissue. These metabolites
were identified as potential oncometabolites associated with LoF
mutations.
To predict LoF oncometabolites, we first modified a
reconstructed cancer model into mutated enzyme deficient
models. For example, as shown in Figure 3B, FASN, ACACB,
and CAD genes were found to be recurrently mutated in
leukemia. For each gene, we built a corresponding leukemia
model with a deficiency in that gene (e.g.. FANS-deficient,
ACACB-deficient, and CAD-deficient leukemia models). We
built a total of 13 mutated enzyme deficient models for nine
genes across nine cancer types that have feasible flux solution
states with the deficient function of the mutated enzyme
(Figure S9 in Text S1).
Once the deficient models were built, we simulated flux changes
that result from the enzyme deficiency by employing an MCMC
sampling method to the enzyme deficient models and matching
normal (no cancer with non-enzyme deficient) models. Substrates
or products of reactions with significantly changed flux for
deficient models as compared to normal models were chosen as
potential oncometabolites. Finally, 15 unique metabolites
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catalyzed by the mutated enzymes and surrounded by significantly
changing flux were predicted as context-specific LoF oncometa-
bolites (Figure 5A). Notably, previously known oncometabolites,
succinate and fumarate, were predicted as potential oncometabo-
lites due to the LoF of SDBH in gastric cancer (Figure 5A, Table
S7 in Text S1) [9–12].
24 dominant substructures of candidate
oncometabolites are predicted as a result of gain-of-
function (GoF) mutations
As described in the example of IDH, mutated enzymes could
possibly confer new catalytic activities by simultaneously changing
the native reaction mechanism and/or catalyzing different
Figure 2. Overall statistics on genetic mutations in metabolic genes. (A) The violin plot depicts the distribution of the number of mutated
enzymatic genes per patient (sample) in each cancer type (Green box: median, red asterisk: average). A median of 5,20 metabolic genes were
mutated per patient (sample). (B) The percentage of mutated metabolic genes per cancer. (C) The percentage of mutation types. Missense mutation
was mostly frequently observed across cancer types.
doi:10.1371/journal.pcbi.1003837.g002
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substrates. In this study, we used a chemoinformatics approach to
predict promiscuous catalytic activities of enzymes resulting from
GoF mutations. This chemoinformatics approach has been shown
to be useful in predicting enzymes promiscuity [30,31], assigning
Enzyme Commission (EC) number [32,33], and analyzing
reaction databases [34].
To predict candidate oncometabolites resulting from promis-
cuous activities of mutated enzymes, a systems framework was
developed to determine new enzyme functionalities due to
mutated enzymes. First, each substrate and product present in
the mutated enzyme reactions were compare against the Human
Metabolome Database (HMDB) [35]. In order to decrease
computational efforts and select a manageable set of metabolites
for biochemical reaction operators (BROs) simulation, Tanimoto
coefficient cut off values were determined for each mutated
enzyme reactions. Then, synthetic reactions were constructed by
applying generic BROs to previously HMDB selected metabolites
(see Materials and Methods for details). Then, simulated
synthetic reactions were compared against the reactions associated
with the mutated enzymatic genes. To do this, Tanimoto
coefficients of substrates and reactions were calculated between
pairs of reactions. In order to emulate the GoF enzyme behavior,
different Tanimoto coefficient cut-off values were imposed on each
reaction according to the IDH GoF mutation case. Pairs of
reactions with Tanimoto similarity scores of less than or equal to a
specific cut-off were saved and identified as possible gain of
function pairs (see Figure S10 in Text S1for details). Finally,
from these reaction pairs, structural features of oncometabolites
were predicted.
Among the 17 genes with recurrent GoF mutations, seven genes
could have catalytic activity in cancer (see Figure S11 inText S1 for
details). The final GoF mutated enzymatic gene list for this analysis
contains seven unique genes. Among the reactions associated with the
seven mutants, reactions catalyzing large molecules that could yield
more than 30,000 promiscuous activities due to the compounds
complexity were excluded from the analysis, and finally 33 reaction
associations were identified from the enzymatic list. Notably, cofactors
were not taken into account for the compound list generation.
A summary of mutated enzymes associated reactions and their
predicted promiscuity catalytic activities is given in Table S8 in
Text S1. For example, for the CAD gene which catalyzing L-
glutamine, 2866 potential promiscuity catalytic reactions associat-
ed with 170 substrates and 1644 products were predicted in CAD
mutant lung (SCC) cancer and gastric cancer (Table S8 in Text
S1, Figure 5B, all detailed information of predicted promiscuity
reactions is shown in the File S2).
In most cases promiscuous substrates show similarities with the
native substrate [36,37]. We conducted compound similarity
analysis in order to demonstrate dominant substructures of
promiscuous substrates and products (Table S8 in Text S1).
The compound structure shown in the Table S8 in Text S1 is the
dominantly observed substructure of promiscuous substrates and
products. Notable, several promiscuous substrates and products
did not have dominant substrates. Finally, we identified 24
Figure 3. Recurrently mutated enzymes in the nine cancer types. (A) The 96 metabolic genes that are recurrently mutated in samples ($ 5%).
The functional pathways in the grey box denote enriched pathways among the 96 genes (Hypergeometric, P , 0.001). (B) The selected 20 metabolic
genes that are recurrently mutated in samples ($ 5%), and are expected to have a significant functional impact from their genomic sequence
mutations in any of nine cancer types. Blue box: recurrently mutated genes for GoF analysis (gene having missense mutations). Red box: recurrently
mutated genes for LoF analysis (genes having nonsense, frame shift indels, splice site indels&SNP mutations).
doi:10.1371/journal.pcbi.1003837.g003
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Figure 4. The accuracy of the reconstructed context-specific GEMs. (A) Pearson’s pairwise correlation plot shows correlation of gene
expression P/A calls (right-bottom; green) and model structures (left-upper; purple) between cancer types. Values next to the correlation plot
represent final correlation between gene expression P/A calls and the network structure for each cancer type, values in parentheses represent P-
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promiscuous compound substructures as features of GoF onco-
metabolites (Figure 5B).
Discussion
In this study, we predicted potential oncometabolites in nine
types of cancer by analyzing the massive scale genetic variants
integrated with cancer and normal GEMs. We first predicted
potential oncometabolites that could result from LoF mutations by
simulating flux changes in the metabolic network due to the LoF of
mutated enzymes. Second, we predicted oncometabolites that
could result from GoF mutations by inferring promiscuous
catalytic activities of enzymes resulting from their GoF mutations.
Setting aside the generally accepted LoF criterion (nonsense,
splice-variants and frame-shift), we rarely have information about
the mutational directionality of a given missense mutation whether
it functions as GoF or LoF. Specifically in the oncometabolite
analysis, enzymes can be disrupted in both ways. Whereas an LoF
of an enzyme gives a predictable malfunctions (e.g. an accumu-
lation of a target product), a GoF mutation is much more
unpredictable and is the very place in which an in silico analysis
should be targeted. As in the example of IDH, IDH gained an
unexpected catalytic activity that is result from missense
mutations. Therefore, in this study, we focused on the possible
metabolic perturbation of a GoF mutation in an enzyme can
raise. Note that, assuming a mutation to be GoF is different
from asserting the mutation is GoF. Using the aforementioned
criteria, we predicted 15 oncometabolites resulting from the
LoF mutations, and 24 substructures of oncometabolites
resulting from the GoF mutations. These predictions can be
used as a guide to examine select mutant enzymes and
generation of oncometabolites. Notably, in our reconstructed
models, several cancer and/or normal models do not uptake
glucose or secrete CO2 in their optimal flux states (optimal
solution). In order to prevent this problem, we allowed small
amounts of uptakes to important vitamins exchange reactions
(Table S4 in Text S1). Also, we constrained models to uptake
glucose, oxygen and secrete CO2, biomass. With the updates,
now most of models produce presumably reasonable uptake
and secrete flux states (see flux variation ranges in the Table
S5, S6 in Text S1). Although still several models do not secrete
any CO2 in the optimal flux states, this problem is not a critical
problem in our study since the representative flux states in our
results were determined from the sampling points within the
suboptimal solution space (90% of optimality solution space)
that is the flux variation ranges shown in the Table S5 and S6
in Text S1.
Altered energy metabolism in cancer cells is accepted as a
hallmark of cancer [2,5]. With the discovery of oncometabolites
such as 2-HG, succinate, and fumarate that originate from
mutations in key enzymes, alteration of metabolism is now
considered to be a strong oncogenic factor. With the existence of
oncometabolites established, there is clearly a great interest in
determining if there are additional metabolites with oncogenic
potential. Large-scale data sets available for a variety of cancers
and genome-scale models of metabolism can be used to predict the
existence of oncometabolites, and can contribute to therapies and
biomarkers in cancer.
Oncometabolites could be used to develop therapies and
identify biomarkers associated with cancer. Recent studies
showed that inhibition of mutant IDH1 delays growth of glioma
cells and induces cellular differentiation in leukemia, which
shows possibility of a potential application as a therapy for
cancer [38,39]. Also, it has been reported that a breast cancer
subtype with elevated level of 2-HG was associated with
reduced survival. This study indicated that high levels of 2-HG
may be a useful biomarker for breast cancer diagnosis and
prognosis [40]. Thus, predicting existence of potential onco-
metabolites would be beneficial in cancer therapies and
biomarker identification.
Materials and Methods
Model setup and parameterization
In order to reconstruct cancer type specific metabolic models
and their paired normal models, we used data sets of gene
expression experiments collected from TCGA consortium and
GEO Database which are composed of expression profiles of
primary cancer cells and site-matched normal cells (Table 1).
In order to maximize platform consistency, we focused on
using Affymetrix and Illumina Hiseq RNA-seq platforms. The
present/absent (P/A) calls of the Affymetrix gene expression
were made using the ‘mas5calls’ function in the ‘affy’ package
(ver. 1.28.0) implemented in R (ver. 2.15.0), and a threshold of
10 read maps was used to define detection of the P/A calls of
RNA-seq data at the gene level [41]. In our study, genes that
are expressed in more than 99% of the total number of samples
in a data set are finally determined as present (expressed)
genes.
The P/A call results of gene expression are then incorporated to
the reactional space using Gene Inactivity Moderated by
Metabolism and Expression (GIMME) algorithm implemented
in COBRA Toolbox v2.0 [42,43]. For the medium condition, a
standard RPMI-1640 condition was used in all simulations
[21,22]. Although, same medium uptake rates were applied to
different cancer and normal models, this is not likely to cause
serious artifacts since the proposed method is based on differences
of network structure of cancer vs. normal models as determined by
gene expression P/A call results.
As cancer cells are known to maximize their proliferation rate,
the biomass formation was maximized in all cancer models
[21,22] (Formula 1). However, normal cells may have different
objectives depending on the growth signals [3], thus we designed
a new objective function which can cover the different cellular
objectives in both proliferative and quiescent normal cells
(Formula 2).
values of significance (Figure S6 in Text S1). (B) The accuracy of the predicted flux changes from the reconstructed models. The prediction of gene
expression changes from changes in flux was tested against gene expression data sets for cancer vs. normal. The black bar depicts the accuracy of the
flux prediction from the reconstructed models. The grey bar denotes the median value of 10,000 accuracies from the random flux. The error bar
shows the standard error mean (SEM) of 10,000 random accuracies. (C) The percent stacked column chart shows the percent of genes for three
categories of gene knockout effects (Essential: knockout effect that reduced the growth rate more than 10%, 1,10% reduced: knockout effect that
reduced the growth rate from 1 to 10%, No change: knockout does not cause any change). (D) The accuracy of a model is evaluated by enrichment
analysis of experimentally validated essential genes among the predicted essential genes with the model. A P-value from the hypergeometric test is
converted to a z-score. Higher z-scores correspond to more significant enrichment (Orange: z-scores of essential genes, yellow: z-scores of genes
causing 9% growth reduction, sky-blue: causing 5% growth reduction, 1%: causing 1% growth reduction).
doi:10.1371/journal.pcbi.1003837.g004
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Figure 5. Predicted oncometabolites. (A) LoF oncometabolites. Metabolites surrounded by reactions with significantly changed flux in themutated
enzyme deficient model compared to the normal model were finally predicted as the potential LoF oncometabolites. The heatmap shows predicted
oncometabolites (black) across nine mutated enzyme deficient cancer models ([m], [c] and [e]: metabolites observed in mitochondria, cytosol, and
extracellular, respectively). (B) GoF oncometabolite substructures. By applying the chemoinformatics approach, promiscuous catalytic activities of
enzymes resulting from their GoF mutations were predicted. The heatmap represents predicted dominant substructrues of promiscuous substrates and
products across seven cancer types. Full list of substructrues of promiscuous substrates and products is shown in the Table S8 in Text S1.
doi:10.1371/journal.pcbi.1003837.g005
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MaximizeVobj cancer~Vbiomass (1)
MaximizeVobj normal~a
Vbiomass
Vmaxbiomass
zb
VATP
VmaxATP
(2)
Subjectto
S.v~0
Because normal cells have different, or multiple, physiological
objectives (i.e., biomass or ATP formation), we constructed an
objective function that was a linear combination of these
physiological functions (Formula 2). Each reaction flux in the
objective function was scaled by its maximum achievable flux in
the given growth condition. The contribution of each component
may be weighted with an additional coefficient (a and b) with a
value of 0 denoting no contribution to the objective. Here,
coefficient a and b are set to be 1 and 1, respectively (equal
contribution of biomass and ATP).
Markov chain Monte Carlo sampling
The distribution of feasible fluxes in the models used in this
study was determined using Markov chain Monte Carlo
(MCMC) sampling [44], and was implemented with the
COBRA Toolbox v2.0 [42]. Specifically, the objective func-
tion was provided a lower bound of 90% of the optimal growth
rate as computed by flux balance analysis [45]. Thus, the
sampled flux distributions represented sub-optimal flux-distri-
butions, but still simulated fluxes relevant to cell growth and
maintenance.
MCMC sampling was used to obtain thousands of feasible flux
distributions using the artificially centered hit-and-run algorithm
with slight modifications, as described previously [46,47]. As a
result, a mixed fraction of approximately 0.50 was obtained,
suggesting that the space of all possible flux distributions is nearly
uniformly sampled.
For each reaction, a distribution of feasible steady-state flux
values was acquired from the uniformly sampled points, subject to
the network topology and model constraints. Similar measures
were taken for all other models in this work.
Flux change prediction in cancer versus normal
To simulate changes in reaction flux occurring in a shift
between cancer and normal, the sampled fluxes for each reaction
were compared between cancer and normal as follows. First,
reactions that carried no flux in both conditions or that were
involved in loops [48] were removed and not used in further
analysis. Next, flux magnitudes were normalized between each
pair of media conditions. To do this, the flux value of each sample
point was divided by the sum of all flux magnitudes for the sample
point (Formula 3).
normalized fluxij~fluxij=
Xn
i~1
abs(fluxij) ð3Þ
n~number of reactions,i~ithreaction,j~jthsample point
Once the flux values were normalized, the changes of fluxes
between two conditions were determined as previously described
[47]. Briefly, differential reaction activity was determined by
assuming that a reaction is differentially activated if the
distributions of feasible flux states (obtained from MCMC
sampling) under two different conditions do not significantly
overlap. For each metabolic reaction, a P-value was obtained
by computing the probability of finding a flux value for a
reaction in one condition that is equal to or more extreme
than a given flux value in the second condition. The
significance of P-values was adjusted for multiple hypotheses
(FDR # 0.01).
Flux versus gene expression changes
The approach presented here extends the pre-published method
called Flux Space Shift analysis (FSS) [49]. FSS utilizes MCMC
sampling of the metabolic solution space to compute the
distribution of all possible steady-state fluxes an enzymatic reaction
can carry in a cell in a given growth condition. For each reaction,
a P-value is computed from the distributions of possible fluxes for
the reaction in a cancer cell and its matched normal cell. This P-
value represents the probability of choosing a flux value from a
reaction in a cancer cell that is also within the distribution for that
reaction in a normal cell. The P-values are then corrected for
multiple hypotheses, and the list of reactions that show signifi-
cantly different fluxes for cancer vs. normal is returned, along with
the direction of the change in magnitude (up or down). All
significantly changed fluxes are then decomposed into a list of
genes that help to catalyze the reactions using the gene-protein-
reaction associations in the model. Through this, one can obtain
lists of genes that are expected to be up-regulated or down-
regulated. Here, in order to minimize the ambiguity, genes that
are associated both with reactions that increase and other
reactions that decrease were removed, and reactions catalyzed
by more than one isoenzyme were also filtered out from the
analysis since not all isozymes are necessarily to change their gene
expression level. Once the lists of genes that are expected to be up-
or down-regulated are gathered, the predictions were compared to
the actual gene expression changes. The accuracy of the prediction
was demonstrated by the ratio of the number of correctly
predicted genes divided by the number of total predictions
(Formula 4). The significance of the accuracy is demonstrated by
a comparison with the background distribution using 10,000
random accuracy tests.
Accuracy~
TPzTN
TPzTNzFPzFN
ð4Þ
(TP: True positive, TN: True negative, FP: False positive, FN:
False negative)
Gene essentiality prediction
Accuracy of reconstructed cancer specific models was
assessed using experimentally determined essential genes. We
collected a list of cancer essential genes from [50]. Ulti-
mately, 14 cancer cell essential metabolic genes which were
reported as common essential genes across 13 cancer cell line
were used.
We performed in silico single gene deletion tests on each model,
and genes whose deletion effect reduces the maximum objective
reaction by more than 10% were determined to be in silico
essential genes. Finally, as the total number of predicted in silico
essential genes varies according to the models, the accuracy of the
models were evaluated with P-values from the hypergeometric
enrichment tests of experimental essential genes against the in
silico essential genes.
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Gain-of-function oncometabolite prediction
Defining similarity (measuring similarities of substrates
and reactions). Mutated enzymes are able to carry out new
catalytic functions by simultaneously changing the native reaction
mechanism and catalyzing different substrates. The changes could
be measured and compared using a chemoinformatic approach.
Previous studies have successfully shown the efficacy of the
chemoinformatic approach for enzyme promiscuity predictions
[30,31], reaction Enzyme Commission (EC) number assignments
[32,33], and reaction database analysis [34]. In this study, native
and nonnative substrates and reactions are represented by a
fingerprint, and the similarity of reactions and substrates were
compared by calculating the corresponding Tanimoto coefficient
between fingerprints.
Chemical representation. For compound and reaction
representation we used MDL Molfiles. A Molfile contains
information about the atoms, bonds, connectivities, and coordi-
nates of a molecule. The Molfile consists of some header
information, the Connection Table containing atom info, then
bond connections and types, followed by sections for more
complex information.
Substrate fingerprint. As stated before, substrates are
represented by chemical fingerprints. The chemical fingerprint
(CFP) of a molecule is defined as CFP = (Fi), in which Fi refers to
a molecular fragment with real occurrences of a molecule. Fi is
obtained by molecular fragmentation method. Each Fi in the
fingerprint is represented in bit string where each position of the
sequence is represented by ‘1’ or ‘0’ digits, depending on the
presence or absence of the structural pattern predefined by Fi.
Previous studies have shown good results by using linear fragments
from 5 up to 6 bonds [32,33]. In order to choose optimal
parameters for the compounds present in the HMDB, the
ChemAxon parameter optimization criteria was used. From this
analysis, the fingerprint length, the maximum fragmentation
pattern length and number of bit in the string were 1024, 6, and 2
respectively.
Reaction fingerprint. In the case of reaction fingerprints, each
compound present in the reaction is represented as a CFP. This
fingerprint is a segmented fingerprint that is constituted from 8
chemical fingerprint sections. This reaction fingerprint representation
allows us to compare reactions from its structural and transforma-
tional features. Parameters were defines as previously stated.
Tanimoto coefficient (TC). The comparison of two finger-
prints involves the calculation of the TC. Values of this metric are
non-negative numbers. Here, we used the TC dissimilarity
(TCdiss) metric. A zero dissimilarity value indicates that the two
fingerprints are identical, and the larger the value of the
dissimilarity coefficient the higher the difference between the
two structures. In its original form, Tanimoto metrics it is a
similarity metric (TCsim, Formula 5):
TCsim~
B(a&b)
B(a)zB(b){B(a&b)
ð5Þ
Where a and b are two binary fingerprints, & denotes binary
bit-wise and-operator, | denotes bit-wise or-operator and B(x) is
the number of 1 bits in any binary fingerprint x:
B(x)~Dfxi~1gDxi[f0,1g; i~1,:::,ngD~
Xn
i~1
xi
From that it is straightforward to obtain a dissimilarity measure
(Formula 6):
Tdiss~1{Tsim ð6Þ
Synthetic reaction construction
For synthetic reaction construction, we first defined a set of 374
irreversible generic biochemical reaction operators (BROs) that
has been used in previous studies, mostly for prediction purposes
for metabolic engineering [51–53], enzyme promiscuity analysis
[31,54], and xenobiotics degradation [55]. These BROs can
represent approximately 75% of enzymes present in the KEGG
Database and 72% of BRENDA EC numbers. Essentially, a BRO
is constructed based on the smallest substructure representing the
structural changes of substrates and products in a specific reaction.
Each BRO is related to specific cofactors and a third-level EC
number for further reaction reconstruction and identification. For
BRO representation, we used SMIRKS [56], a language used for
describing generic reactions (transformations) by using SMARTS
[56] representation of the reaction’s substructures. A SMARTS
pattern may include not only a specification of reaction center, but
also a specification of a local structure that must occur or is
necessarily absent based on our best understanding of the relevant
biochemistry [57]. After BRO construction, we generate all
possible reactions that may occur and every compound that may
be produced given the previous selected list of human metabolites.
Then, specific cofactors were assigned, and for filtering purposes
mass balance was performed.
Compound clustering analysis
For each mutated enzyme, Maximum Common Substructure
(MCS) analysis was used in order to identify the most common
chemical patter from all predicted products and substrates. The
idea is to identify from a range of chemical structures, the largest
substructure common in all of them.
For all calculations, with regard to handling compounds,
building reaction, substrate fingerprint generation, reaction
fingerprint generation, TC dissimilarity calculations, BROs
simulations, and MCS analysis we used MATLAB linked with
ChemAxon’s package libraries, specifically Marvin, JChem Base,
Standardizer and Reactor [(ChemAxon, Budapest,Hungary,
www.chemaxon.com)].
Supporting Information
File S1 Full list of 96 recurrently mutated enzyme encoding
metabolic genes and their mutation rates.
(XLSX)
File S2 All detailed information of predicted promiscuity
reactions for GoF analysis.
(XLSX)
File S3 18 cancer and normal genome-scale metabolic models in
SBML.
(ZIP)
Text S1 Supporting results including supporting figures, tables,
and text.
(PDF)
Prediction of Oncometabolites In Silico
PLOS Computational Biology | www.ploscompbiol.org 12 September 2014 | Volume 10 | Issue 9 | e1003837
Author Contributions
Conceived and designed the experiments: HN MC BOP. Performed the
experiments: HN MC SK. Analyzed the data: HN MC DRH SK.
Contributed reagents/materials/analysis tools: HN MC AB SK DCZ.
Wrote the paper: HN MC AB DRH SK DCZ BOP.
References
1. Warburg O, Posener K, Negelein E (1924) Ueber den stoffwechsel der tumoren.
Biochem Z 152: 319–344.
2. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell
144: 646–674.
3. Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the
Warburg effect: the metabolic requirements of cell proliferation. Science 324:
1029–1033.
4. Cairns RA, Harris IS, Mak TW (2011) Regulation of cancer cell metabolism.
Nat Rev Cancer 11: 85–95.
5. Ward PS, Thompson CB (2012) Metabolic reprogramming: a cancer hallmark
even warburg did not anticipate. Cancer Cell 21: 297–308.
6. Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, et al. (2012) IDH mutation
impairs histone demethylation and results in a block to cell differentiation.
Nature 483: 474–478.
7. Xu W, Yang H, Liu Y, Yang Y, Wang P, et al. (2011) Oncometabolite 2-
hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent
dioxygenases. Cancer Cell 19: 17–30.
8. Letouze E, Martinelli C, Loriot C, Burnichon N, Abermil N, et al. (2013) SDH
mutations establish a hypermethylator phenotype in paraganglioma. Cancer
Cell 23: 739–752.
9. Yang M, Soga T, Pollard PJ, Adam J (2012) The emerging role of fumarate as
an oncometabolite. Front Oncol 2: 85.
10. Xiao M, Yang H, Xu W, Ma S, Lin H, et al. (2012) Inhibition of alpha-KG-
dependent histone and DNA demethylases by fumarate and succinate that are
accumulated in mutations of FH and SDH tumor suppressors. Genes Dev 26:
1326–1338.
11. Pollard PJ, Briere JJ, Alam NA, Barwell J, Barclay E, et al. (2005) Accumulation of
Krebs cycle intermediates and over-expression of HIF1alpha in tumours which
result from germline FH and SDH mutations. Hum Mol Genet 14: 2231–2239.
12. Isaacs JS, Jung YJ, Mole DR, Lee S, Torres-Cabala C, et al. (2005) HIF
overexpression correlates with biallelic loss of fumarate hydratase in renal
cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 8: 143–
153.
13. Prensner JR, Chinnaiyan AM (2011) Metabolism unhinged: IDH mutations in
cancer. Nat Med 17: 291–293.
14. Thiele I, Swainston N, Fleming RM, Hoppe A, Sahoo S, et al. (2013) A
community-driven global reconstruction of human metabolism. Nat Biotechnol
31: 419–425.
15. Orth JD, Conrad TM, Na J, Lerman JA, Nam H, et al. (2011) A comprehensive
genome-scale reconstruction of Escherichia coli metabolism-2011. Mol Syst Biol
7: 535.
16. Bordbar A, Palsson BO (2012) Using the reconstructed genome-scale human
metabolic network to study physiology and pathology. J Intern Med 271: 131–
141.
17. Osterlund T, Nookaew I, Nielsen J (2012) Fifteen years of large scale metabolic
modeling of yeast: developments and impacts. Biotechnol Adv 30: 979–988.
18. McCloskey D, Palsson BO, Feist AM (2013) Basic and applied uses of genome-
scale metabolic network reconstructions of Escherichia coli. Mol Syst Biol 9: 661.
19. Jerby L, Ruppin E (2012) Predicting drug targets and biomarkers of cancer via
genome-scale metabolic modeling. Clin Cancer Res 18: 5572–5584.
20. Duarte NC, Becker SA, Jamshidi N, Thiele I, Mo ML, et al. (2007) Global
reconstruction of the human metabolic network based on genomic and bibliomic
data. Proc Natl Acad Sci U S A 104: 1777–1782.
21. Shlomi T, Benyamini T, Gottlieb E, Sharan R, Ruppin E (2011) Genome-scale
metabolic modeling elucidates the role of proliferative adaptation in causing the
Warburg effect. PLoS Comput Biol 7: e1002018.
22. Folger O, Jerby L, Frezza C, Gottlieb E, Ruppin E, et al. (2011) Predicting
selective drug targets in cancer through metabolic networks. Mol Syst Biol 7: 501.
23. Frezza C, Zheng L, Folger O, Rajagopalan KN, MacKenzie ED, et al. (2011)
Haem oxygenase is synthetically lethal with the tumour suppressor fumarate
hydratase. Nature 477: 225–228.
24. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, et al. (2012)
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer
drug sensitivity. Nature 483: 603–607.
25. Genomes Project C, Abecasis GR, Auton A, Brooks LD, DePristo MA, et al.
(2012) An integrated map of genetic variation from 1,092 human genomes.
Nature 491: 56–65.
26. MacArthur DG, Balasubramanian S, Frankish A, Huang N, Morris J, et al.
(2012) A systematic survey of loss-of-function variants in human protein-coding
genes. Science 335: 823–828.
27. Reva B, Antipin Y, Sander C (2011) Predicting the functional impact of protein
mutations: application to cancer genomics. Nucleic Acids Res 39: e118.
28. Gnad F, Baucom A, Mukhyala K, Manning G, Zhang Z (2013) Assessment of
computational methods for predicting the effects of missense mutations in
human cancers. BMC Genomics 14 Suppl 3: S7.
29. Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, et al. (2000) Systematic
variation in gene expression patterns in human cancer cell lines. Nat Genet 24:
227–235.
30. Hu QN, Deng Z, Hu H, Cao DS, Liang YZ (2011) RxnFinder: biochemical
reaction search engines using molecular structures, molecular fragments and
reaction similarity. Bioinformatics 27: 2465–2467.
31. de Groot MJ, van Berlo RJ, van Winden WA, Verheijen PJ, Reinders MJ, et al.
(2009) Metabolite and reaction inference based on enzyme specificities.
Bioinformatics 25: 2975–2982.
32. Latino DA, Aires-de-Sousa J (2009) Assignment of EC numbers to enzymatic
reactions with MOLMAP reaction descriptors and random forests. J Chem Inf
Model 49: 1839–1846.
33. HuQN, ZhuH, Li X, ZhangM,Deng Z, et al. (2012) Assignment of ECNumbers to
Enzymatic Reactions with Reaction Difference Fingerprints. PLoS One 7: e52901.
34. Holliday GL, Andreini C, Fischer JD, Rahman SA, Almonacid DE, et al. (2012)
MACiE: exploring the diversity of biochemical reactions. Nucleic Acids Res 40:
D783–789.
35. Wishart DS, Knox C, Guo AC, Eisner R, Young N, et al. (2009) HMDB: a
knowledgebase for the human metabolome. Nucleic Acids Res 37: D603–610.
36. Babtie A, Tokuriki N, Hollfelder F (2010) What makes an enzyme promiscuous?
Curr Opin Chem Biol 14: 200–207.
37. Khersonsky O, Tawfik DS (2010) Enzyme promiscuity: a mechanistic and
evolutionary perspective. Annu Rev Biochem 79: 471–505.
38. Wang F, Travins J, DeLaBarre B, Penard-Lacronique V, Schalm S, et al. (2013)
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular
differentiation. Science 340: 622–626.
39. Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, et al. (2013) An
inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma
cells. Science 340: 626–630.
40. Terunuma A, Putluri N, Mishra P, Mathe EA, Dorsey TH, et al. (2014) MYC-
driven accumulation of 2-hydroxyglutarate is associated with breast cancer
prognosis. J Clin Invest 124: 398–412.
41. illumina (2011) RNA-seq Data Comparison with Gene Expression Microarrays.
illumina White Paper: illumina.
42. Schellenberger J, Que R, Fleming RM, Thiele I, Orth JD, et al. (2011)
Quantitative prediction of cellular metabolism with constraint-based models: the
COBRA Toolbox v2.0. Nat Protoc 6: 1290–1307.
43. Becker SA, Palsson BO (2008) Context-specific metabolic networks are
consistent with experiments. PLoS Comput Biol 4: e1000082.
44. Schellenberger J, Palsson BO (2009) Use of randomized sampling for analysis of
metabolic networks. J Biol Chem 284: 5457–5461.
45. Orth JD, Thiele I, Palsson BO (2010) What is flux balance analysis? Nat
Biotechnol 28: 245–248.
46. Lewis NE, Hixson KK, Conrad TM, Lerman JA, Charusanti P, et al. (2010)
Omic data from evolved E. coli are consistent with computed optimal growth
from genome-scale models. Mol Syst Biol 6: 390.
47. Bordbar A, Lewis NE, Schellenberger J, Palsson BO, Jamshidi N (2010) Insight
into human alveolar macrophage and M. tuberculosis interactions via metabolic
reconstructions. Mol Syst Biol 6: 422.
48. Beard DA, Liang SD, Qian H (2002) Energy balance for analysis of complex
metabolic networks. Biophys J 83: 79–86.
49. Nam H, Lewis NE, Lerman JA, Lee DH, Chang RL, et al. (2012) Network
context and selection in the evolution to enzyme specificity. Science 337: 1101–
1104.
50. Luo B, Cheung HW, Subramanian A, Sharifnia T, Okamoto M, et al. (2008)
Highly parallel identification of essential genes in cancer cells. Proc Natl Acad
Sci U S A 105: 20380–20385.
51. Hatzimanikatis V, Li C, Ionita JA, Henry CS, Jankowski MD, et al. (2005)
Exploring the diversity of complex metabolic networks. Bioinformatics 21: 1603–
1609.
52. Henry CS, Broadbelt LJ, Hatzimanikatis V (2010) Discovery and analysis of
novel metabolic pathways for the biosynthesis of industrial chemicals: 3-
hydroxypropanoate. Biotechnol Bioeng 106: 462–473.
53. Yim H, Haselbeck R, Niu W, Pujol-Baxley C, Burgard A, et al. (2011) Metabolic
engineering of Escherichia coli for direct production of 1,4-butanediol. Nat
Chem Biol 7: 445–452.
54. Mu F, Unkefer CJ, Unkefer PJ, Hlavacek WS (2011) Prediction of metabolic
reactions based on atomic and molecular properties of small-molecule
compounds. Bioinformatics 27: 1537–1545.
55. Finley SD, Broadbelt LJ, Hatzimanikatis V (2009) Computational framework for
predictive biodegradation. Biotechnol Bioeng 104: 1086–1097.
56. James CA, Weininger D, Delany J (2004) Daylight theory manual. Aliso Viejo:
Daylight chemical information systems, Inc.
57. Silverman RB (2002) Organic Chemistry of Enzyme-Catalyzed Reactions:
Academic Press.
Prediction of Oncometabolites In Silico
PLOS Computational Biology | www.ploscompbiol.org 13 September 2014 | Volume 10 | Issue 9 | e1003837
